Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma
Open Access
- 11 September 2007
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 139 (1) , 55-63
Abstract
Summary: Osteolytic bone disease in multiple myeloma (MM) is associated with upregulation of osteoclast (OCL) activity and constitutive inhibition of osteoblast function. The extracellular signal‐regulated kinase 1/2 (ERK1/2) pathway mediates OCL differentiation and maturation. We hypothesized that inhibition of ERK1/2 could prevent OCL differentiation and downregulate OCL function. It was found that AZD6244, a mitogen‐activated or extracellular signal‐regulated protein kinase (MEK) inhibitor, blocked OCL differentiation and formation in a dose‐dependent manner, evidenced by decreasedαVβ3‐integrin expression and tartrate‐resistant acid phosphatase positive (TRAP+) cells. Functional dentine disc cultures showed inhibition of OCL‐induced bone resorption by AZD6244. Major MM growth and survival factors produced by OCLs including B‐cell activation factor (BAFF) and a proliferation‐inducing ligand (APRIL), as well as macrophage inflammatory protein (MIP‐1α), which mediates OCL differentiation and MM, were also significantly inhibited by AZD6244. In addition to ERK inhibition, NFATc1 (nuclear factor of activated T‐cells, cytoplasmic, calcineurin‐dependent 1) and c‐fos were both downregulated, suggesting that AZD6244 targets a later stage of OCL differentiation. These results indicate that AZD6244 inhibits OCL differentiation, formation and bone resorption, thereby abrogating paracrine MM cell survival in the bone marrow microenvironment. The present study therefore provides a preclinical rationale for the evaluation of AZD6244 as a potential new therapy for patients with MM.Keywords
This publication has 44 references indexed in Scilit:
- ZD6474 induces growth arrest and apoptosis of human leukemia cells, which is enhanced by concomitant use of a novel MEK inhibitor, AZD6244Leukemia, 2007
- Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinomaMolecular Cancer Therapeutics, 2007
- M-CSF induces the stable interaction of cFms with αVβ3 integrin in osteoclastsThe International Journal of Biochemistry & Cell Biology, 2006
- Significance of macrophage inflammatory protein-1 alpha (MIP-1α) in multiple myelomaLeukemia & Lymphoma, 2005
- Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansionBlood, 2004
- The role of the BAFF/APRIL system in B cell homeostasis and lymphoid cancersCurrent Opinion in Pharmacology, 2004
- Association of sustained ERK activity with integrin β3 induction during receptor activator of nuclear factor kappaB ligand (RANKL)-directed osteoclast differentiationExperimental Cell Research, 2003
- Osteoclast differentiation and activationNature, 2003
- Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieuBlood, 2003
- Molecular interpretation of ERK signal duration by immediate early gene productsNature Cell Biology, 2002